A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
NCT04895709
This study is recruiting at 8 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with advanced solid tumors.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Cervical Cancer
- Gastric/Gastroesophageal Junction Adenocarcinoma
- Microsatellite Stable Colorectal Cancer
- Non-Small-Cell Lung Cancer
- Squamous Cell Carcinoma of Head and Neck
- Carcinoma, Renal Cell
- Urothelial Carcinoma
- Pancreatic Adenocarcinoma
- Melanoma
- Ovarian Neoplasms
- Triple Negative Breast Neoplasms
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Bristol-Myers Squibb
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 3
- Community Cancer Institute · Clovis, CA
- USC/Norris Comprehensive Cancer Center · Los Angeles, CA
- Hoag Memorial Hospital Presbyterian · Newport Beach, CA
Iowa · 1
- University of Iowa · Iowa City, IA
New Jersey · 1
- John Theurer Cancer Center · Hackensack, NJ
Oregon · 1
- Providence Cancer Center Oncology and Hematology Care- Eastside · Portland, OR
Tennessee · 1
- Vanderbilt University Medical Center · Nashville, TN
Texas · 1
- Houston Methodist Hospital · Houston, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.